UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
European heart journal, ISSN 0195-668X, 01/2018, Volume 39, Issue 2, pp. 119 - 177
Emergency medical system | Primary percutaneous coronary intervention | Quality indicators | Antithrombotics | Fibrinolysis | ST-segment elevation | Guidelines | Reperfusion therapy | Antithrombotic therapy | MINOCA | Risk assessment | Secondary prevention | Evidence | Acute coronary syndromes | Acute myocardial infarction | Ischaemic heart disease
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. 7S - 47S
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Societies, Medical | United States | Fibrinolytic Agents - therapeutic use | Humans | Thrombosis - drug therapy | Thrombosis - prevention & control | Evidence-Based Medicine | Practice Guidelines as Topic | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th ed | American College of Chest Physicians Evidence-based Clinical Practice Guidelines
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e278S - e325S
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Pulmonary Embolism - prevention & control | Drug Administration Schedule | Intermittent Pneumatic Compression Devices | Humans | Risk Factors | Postoperative Complications - blood | Postoperative Complications - prevention & control | Combined Modality Therapy | Hemorrhage - blood | Hemorrhage - prevention & control | Evidence-Based Medicine | Venous Thromboembolism - drug therapy | Pulmonary Embolism - blood | Venous Thromboembolism - blood | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Venous Thromboembolism - prevention & control | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Orthopedic Procedures | Fibrinolytic Agents - therapeutic use | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Postoperative Complications - drug therapy | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article